A new clinical trial has been announced, aiming to explore the potential benefits of combining the traditional Chinese medicine Huangjing Yangji Formula with standardized resistance training for managing sarcopenia. This initiative, sponsored by notable institutions such as Wangjing Hospital and other leading Chinese medical universities, is a significant development in addressing muscle loss associated with aging. Professionals in clinical research, quality assurance, and regulatory compliance may find the study especially relevant.
As of January 10, 2026, the trial has yet to begin recruiting participants.
In this article:
What changed?
This announcement introduces a trial combining a standardized elastic band resistance training protocol with the Huangjing Yangji Formula. The focus is to assess the formula’s potential to improve muscle mass, strength, and function in patients with sarcopenia. While resistance training is a well-validated approach to managing this condition, the inclusion of traditional Chinese medicine adds a novel dimension to potential therapeutic strategies.
What is sarcopenia?
Sarcopenia is a condition characterized by the loss of skeletal muscle mass and strength, predominantly affecting older adults. This age-related muscle degeneration impacts mobility, increases risk of falls, and reduces quality of life. Current management strategies focus on lifestyle changes, including exercise regimens and nutritional adjustments, with few effective pharmacological interventions available.
Study details
Sponsors and collaboration
The study is backed by prominent institutions, including:
- Wangjing Hospital, China Academy of Chinese Medical Sciences;
- The First Affiliated Hospital of Tianjin University of Traditional Chinese Medicine;
- Hunan University of Traditional Chinese Medicine.
This collaboration underscores the seriousness with which the research community is addressing sarcopenia.
Interventions
The trial will investigate three key interventions:
- Huangjing Yangji Formula Granules: A traditional Chinese medicine formula of interest for its potential muscle-supporting properties.
- Placebo Granules: Used as a control to measure the efficacy of the Huangjing Yangji Formula.
- Standardized Elastic Band Resistance Training: A behavioral intervention that has demonstrated efficacy in previous studies by improving muscle strength and balance.
Trial phase and recruitment
The study is listed as “Not yet recruiting” as of the noted January 2026 update. Interested participants and professionals can monitor updates at the official ClinicalTrials.gov link provided below.
Why this trial matters
This trial represents a step forward in integrating traditional medical approaches with modern exercise science for sarcopenia. It can potentially identify new, complementary treatment options that address both preventative and therapeutic strategies.
Frequently Asked Questions
- What does the study aim to achieve?
The goal is to determine the efficacy of combining Huangjing Yangji Formula with resistance training in improving outcomes for sarcopenia patients. - Who is sponsoring the study?
Major sponsors include Wangjing Hospital, China Academy of Chinese Medical Sciences, and two additional Chinese medical universities. - When will recruitment begin?
Recruitment has not started as of January 2026. Stay tuned for updates via the provided ClinicalTrials.gov link. - Can I access further trial details?
Yes. Visit the official trial page linked at the end of this article for full study information.
Conclusion
This trial leverages both traditional and modern approaches to tackle sarcopenia, promising a novel integration of Chinese medicine and resistance training. Stakeholders in clinical research and therapeutic innovation will find this study useful in addressing age-related muscle loss.
Disclaimer
This article provides regulatory and clinical insights for professionals. It is not legal or medical advice. Individuals should consult qualified advisors for specific guidance.
Announcement Details
For full information about the announcement, see the link below.
https://clinicaltrials.gov/study/NCT07321535?term=medical+device